Sanofi and Regeneron's Dupixent Scores Another Approval for Dermatitis, This Time in Kids

Just a day after Paris-based Sanofi announced it was selling off almost $13 billion in investment in its longtime development partner Regeneron Pharmaceuticals, the U.S. Food and Drug Administration (FDA) approved their Dupixent (dupilumab) for children ages 6 to 11 years with moderate-to-severe atopic dermatitis. To date, Dupixent is the only biologic approved for this age group.